JP7458032B2 - 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 - Google Patents
出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Download PDFInfo
- Publication number
- JP7458032B2 JP7458032B2 JP2020561786A JP2020561786A JP7458032B2 JP 7458032 B2 JP7458032 B2 JP 7458032B2 JP 2020561786 A JP2020561786 A JP 2020561786A JP 2020561786 A JP2020561786 A JP 2020561786A JP 7458032 B2 JP7458032 B2 JP 7458032B2
- Authority
- JP
- Japan
- Prior art keywords
- centaquine
- blood
- pharmaceutical composition
- renal
- rats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666675P | 2018-05-03 | 2018-05-03 | |
| US62/666,675 | 2018-05-03 | ||
| IN201841019588 | 2018-05-25 | ||
| IN201841019588 | 2018-05-25 | ||
| PCT/US2019/030652 WO2019213558A1 (en) | 2018-05-03 | 2019-05-03 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523125A JP2021523125A (ja) | 2021-09-02 |
| JP2021523125A5 JP2021523125A5 (cg-RX-API-DMAC7.html) | 2022-05-13 |
| JP7458032B2 true JP7458032B2 (ja) | 2024-03-29 |
Family
ID=68386694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561786A Active JP7458032B2 (ja) | 2018-05-03 | 2019-05-03 | 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12629406B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3813942B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7458032B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112469474A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019262612B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020022395A2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2978951T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3813942T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019213558A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2424529T3 (pl) | 2009-04-30 | 2017-06-30 | Midwestern University | Nowe postępowania terapeutyczne z zastosowaniem centakwiny |
| CN112469474A (zh) | 2018-05-03 | 2021-03-09 | 美国中西部大学 | 出血和centhaquin引起的复苏后内皮素受体的变化 |
| WO2022240964A1 (en) * | 2021-05-11 | 2022-11-17 | Pharmazz, Inc. | Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19) |
| US20240207356A1 (en) * | 2022-12-26 | 2024-06-27 | Pharmazz, Inc. | Composition and method for wound healing and repair of damaged nerves |
| US20240382461A1 (en) * | 2023-05-15 | 2024-11-21 | Pharmazz, Inc. | Pharmaceutical composition and method for prevention and treatment of hearing loss |
| IN202411028038A (cg-RX-API-DMAC7.html) * | 2024-04-04 | 2025-05-23 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992019644A1 (fr) | 1991-04-24 | 1992-11-12 | Banyu Pharmaceutical Co., Ltd. | Peptide vasodilatateur |
| JP2010523584A (ja) | 2007-04-02 | 2010-07-15 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ピリミジン |
| JP2010523694A (ja) | 2007-04-10 | 2010-07-15 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 高血圧治療のための置換重水素濃縮チオフェン |
| JP2010536880A (ja) | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
| JP2012525422A (ja) | 2009-04-30 | 2012-10-22 | ミッドウェスタン ユニバーシティ | センタキンを用いた新規の治療方法 |
| US20130296331A1 (en) | 2010-11-26 | 2013-11-07 | Technion Research And Development Foundation Ltd. | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
| JP2015530385A (ja) | 2012-08-31 | 2015-10-15 | ファーマズ,インコーポレイテッド | 低血圧蘇生のための方法および組成物 |
| JP2016523969A (ja) | 2013-07-08 | 2016-08-12 | ミッドウェスタン ユニバーシティ | エンドセリンb受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954987A (en) | 1972-12-22 | 1976-05-04 | Sandoz, Inc. | 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock |
| DE2421382A1 (de) | 1974-05-03 | 1975-11-20 | Council Scient Ind Res | 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge |
| JPS604186B2 (ja) | 1974-05-13 | 1985-02-01 | カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ | 1―m―トリル―4―(B―2―キノリエチル)―ピペラジンの製造法 |
| US3983121A (en) | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| DE2557784C2 (de) | 1975-12-22 | 1986-04-17 | Hoechst Ag, 6230 Frankfurt | Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate |
| US4761417A (en) | 1982-05-14 | 1988-08-02 | Maroko Peter R | Compounds, compositions and method of treatments for improving circulatory performance |
| EP0126327A1 (en) | 1983-04-26 | 1984-11-28 | Frank J. Macri | Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same |
| US5055470A (en) | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
| US5922681A (en) | 1992-09-14 | 1999-07-13 | Warner-Lambert Company | Endothelin antagonists |
| US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6369114B1 (en) | 1999-11-30 | 2002-04-09 | Institute Of Critical Care Medicine | Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation |
| GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| SE0004455D0 (sv) | 2000-12-01 | 2000-12-01 | Milos Pekny | Method for neuron regeneration in the central nervous system |
| US6573285B2 (en) | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030232787A1 (en) | 2001-05-08 | 2003-12-18 | Dooley David James | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| US20030104976A1 (en) | 2001-07-23 | 2003-06-05 | Gudarz Davar | Analgesic methods using endothelin receptor ligands |
| US7030082B2 (en) | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US20070066568A1 (en) * | 2005-08-31 | 2007-03-22 | Dalton James T | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| CN1729012B (zh) | 2002-10-24 | 2013-05-22 | 伊利诺伊大学评议会 | 治疗实体瘤的组合物 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US20050009847A1 (en) | 2002-11-20 | 2005-01-13 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| US7906140B2 (en) * | 2004-06-17 | 2011-03-15 | Virun, Inc. | Compositions for mucosal delivery of agents |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
| JP4976412B2 (ja) * | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| JP2009530407A (ja) | 2006-03-23 | 2009-08-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト |
| PL2182977T3 (pl) | 2007-08-21 | 2017-01-31 | Midwestern University | Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B |
| US20100189802A1 (en) | 2007-08-21 | 2010-07-29 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for treatment of vascular hyperpermeability |
| CN101374259B (zh) | 2007-08-22 | 2012-08-08 | 华为技术有限公司 | 实现多媒体彩铃和多媒体彩像业务的方法和装置 |
| EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| WO2011159854A1 (en) | 2010-06-17 | 2011-12-22 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of ccr2 |
| KR101418941B1 (ko) | 2011-04-04 | 2014-07-15 | 서울대학교병원 | 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물 |
| CN112469474A (zh) | 2018-05-03 | 2021-03-09 | 美国中西部大学 | 出血和centhaquin引起的复苏后内皮素受体的变化 |
| JP2025149692A (ja) | 2024-03-26 | 2025-10-08 | ローム株式会社 | 無線通信回路 |
| JP2026006612A (ja) | 2024-06-28 | 2026-01-16 | 多摩川精機株式会社 | 温度検出体固定用溝付き絶縁キャップ、回転電機の温度検出体固定構造、温度検出体固定済み回転電機、回転電機の温度検出体固定方法、および回転電機製造装置 |
-
2019
- 2019-05-03 CN CN201980038669.0A patent/CN112469474A/zh active Pending
- 2019-05-03 PL PL19796519.7T patent/PL3813942T3/pl unknown
- 2019-05-03 AU AU2019262612A patent/AU2019262612B2/en active Active
- 2019-05-03 BR BR112020022395-6A patent/BR112020022395A2/pt not_active Application Discontinuation
- 2019-05-03 US US17/052,473 patent/US12629406B2/en active Active
- 2019-05-03 EP EP19796519.7A patent/EP3813942B1/en active Active
- 2019-05-03 JP JP2020561786A patent/JP7458032B2/ja active Active
- 2019-05-03 EP EP24163271.0A patent/EP4364811A3/en active Pending
- 2019-05-03 WO PCT/US2019/030652 patent/WO2019213558A1/en not_active Ceased
- 2019-05-03 ES ES19796519T patent/ES2978951T3/es active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992019644A1 (fr) | 1991-04-24 | 1992-11-12 | Banyu Pharmaceutical Co., Ltd. | Peptide vasodilatateur |
| JP2010523584A (ja) | 2007-04-02 | 2010-07-15 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ピリミジン |
| JP2010523694A (ja) | 2007-04-10 | 2010-07-15 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 高血圧治療のための置換重水素濃縮チオフェン |
| JP2010536880A (ja) | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
| JP2012525422A (ja) | 2009-04-30 | 2012-10-22 | ミッドウェスタン ユニバーシティ | センタキンを用いた新規の治療方法 |
| US20130296331A1 (en) | 2010-11-26 | 2013-11-07 | Technion Research And Development Foundation Ltd. | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
| JP2015530385A (ja) | 2012-08-31 | 2015-10-15 | ファーマズ,インコーポレイテッド | 低血圧蘇生のための方法および組成物 |
| JP2016523969A (ja) | 2013-07-08 | 2016-08-12 | ミッドウェスタン ユニバーシティ | エンドセリンb受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法 |
Non-Patent Citations (3)
| Title |
|---|
| MIGUEL, C. D. et al.,Endothelinreceptor-specific control of endoplasmic reticulum stress and apoptosis in thekidney,Sci. Rep.,2017年,vol. 7, 43152,p. 1-13 |
| SRIMAL, R. C. et al.,Studies on 2-2-(4-(3-methylphenyl)1-piperazinyl)ethyl quinoline (centhaquin), a centrallyacting antihypertensive. II, Effect on cardiohaemodynamics,Asia pacific journal ofpharmacology,1990年,Vol 5, No. 3,pp 185-190 |
| 菱田 明,急性腎不全,日腎会誌,2002年,vol. 44, no. 2,p. 94-101 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3099128A1 (en) | 2019-11-07 |
| US20210169978A1 (en) | 2021-06-10 |
| EP3813942A4 (en) | 2022-01-19 |
| EP3813942B1 (en) | 2024-04-17 |
| CN112469474A (zh) | 2021-03-09 |
| BR112020022395A2 (pt) | 2021-04-13 |
| AU2019262612A1 (en) | 2020-11-26 |
| EP4364811A3 (en) | 2024-07-10 |
| EP4364811A2 (en) | 2024-05-08 |
| ES2978951T3 (es) | 2024-09-23 |
| PL3813942T3 (pl) | 2024-07-22 |
| WO2019213558A1 (en) | 2019-11-07 |
| EP3813942A1 (en) | 2021-05-05 |
| US12629406B2 (en) | 2026-05-19 |
| JP2021523125A (ja) | 2021-09-02 |
| AU2019262612B2 (en) | 2025-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019262612B2 (en) | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | |
| AU2012388759B2 (en) | Methods and compositions for hypotensive resuscitation | |
| KR100445946B1 (ko) | 폐고혈압 치료법 | |
| US20200375953A1 (en) | Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists | |
| PT1401416E (pt) | Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii) | |
| CA3099128C (en) | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | |
| WO2021037212A9 (zh) | 用于对抗代谢疾病的组合物及其用途 | |
| Abdallah | New trends in pharmacological treatment of acute kidney injury | |
| CN107243004B (zh) | 一种五味子乙素在药物制备中的应用 | |
| JP6861162B2 (ja) | アポエクオリン含有組成物および神経細胞の炎症を治療するためのアポエクオリンの使用方法 | |
| AU2017249459A1 (en) | Treatment of renal cell carcinoma with lenvatinib and everolimus | |
| CN117396505A (zh) | 治疗炎症的方法 | |
| Briyal et al. | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | |
| JP2019513727A (ja) | レンバチニブ及びエベロリムスを用いた腎細胞癌の治療 | |
| AU2015203036A1 (en) | Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists | |
| Saleem et al. | Nephroprotective effect of octreotide and liraglutide in renal ischemia reperfusion injury in mice | |
| KR20180128452A (ko) | Nsaid-유도된 심혈관, 뇌혈관, 또는 신혈관 부작용을 치료하는 방법 | |
| KR20200139447A (ko) | 항염증 조성물 | |
| Hsieh | Pancreatic expression of trpa1, its role in insulin secretion and its possible effect on postprandial blood glucose levels | |
| Buckley et al. | Dr Maria Buckley, Department Pharmacology & Therapeutics, Department of Physiology, APC Microbiome Institute, University College Cork, Cork, Ireland.“Ghrelin enhances GLP-1 induced neuronal activation in the distal colon.” | |
| KR20020045552A (ko) | 만성 폐색성 폐질환의 치료 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230822 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240220 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240308 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7458032 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |